Contributions
Abstract: EP1545
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Background: Autologous haematopoietic stem cell transplant (AHSCT) has been investigated as a therapeutic option for multiple sclerosis (MS) over the last two decades, with sustained and impressive progression- free survival rates up to 15 years. We report a case of relapsing tumefactive MS post AHSCT for relapsing- remitting MS (RRMS).
Case presentation: A 51- year old Chinese Singaporean woman presented with subacute left sided hemiparesis and her magnetic resonance imaging (MRI) of the brain showed multiple large lesions with incomplete ring enhancement and perilesional oedema with minimal mass effect. She was eventually diagnosed with relapsed tumefactive MS. Prior to this presentation, she has been diagnosed with RRMS for 11 years and was treated with AHSCT 3 years after diagnosis in view of aggressive disease course. Her Expanded Disability Status Scale (EDSS) at time of AHSCT and prior to current presentation were 4.0 and 1.0 respectively. She was treated with a short course (5 days) of IV Methylprednisolone, followed by Interferon beta- 1a.
Conclusion: We highlighted the occurrence of tumefactive MS as a presentation of MS relapse and reviewed the major differential diagnoses of brain mass lesions in a patient who has previously been treated with AHSCT.
Disclosure: Kok Pin Yong: nothing to disclose
Pavanni Ratnagopal: nothing to disclose
Abstract: EP1545
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Background: Autologous haematopoietic stem cell transplant (AHSCT) has been investigated as a therapeutic option for multiple sclerosis (MS) over the last two decades, with sustained and impressive progression- free survival rates up to 15 years. We report a case of relapsing tumefactive MS post AHSCT for relapsing- remitting MS (RRMS).
Case presentation: A 51- year old Chinese Singaporean woman presented with subacute left sided hemiparesis and her magnetic resonance imaging (MRI) of the brain showed multiple large lesions with incomplete ring enhancement and perilesional oedema with minimal mass effect. She was eventually diagnosed with relapsed tumefactive MS. Prior to this presentation, she has been diagnosed with RRMS for 11 years and was treated with AHSCT 3 years after diagnosis in view of aggressive disease course. Her Expanded Disability Status Scale (EDSS) at time of AHSCT and prior to current presentation were 4.0 and 1.0 respectively. She was treated with a short course (5 days) of IV Methylprednisolone, followed by Interferon beta- 1a.
Conclusion: We highlighted the occurrence of tumefactive MS as a presentation of MS relapse and reviewed the major differential diagnoses of brain mass lesions in a patient who has previously been treated with AHSCT.
Disclosure: Kok Pin Yong: nothing to disclose
Pavanni Ratnagopal: nothing to disclose